1. Home
  2. COUR vs LQDA Comparison

COUR vs LQDA Comparison

Compare COUR & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COUR
  • LQDA
  • Stock Information
  • Founded
  • COUR 2012
  • LQDA 2004
  • Country
  • COUR United States
  • LQDA United States
  • Employees
  • COUR N/A
  • LQDA N/A
  • Industry
  • COUR Computer Software: Prepackaged Software
  • LQDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • COUR Technology
  • LQDA Health Care
  • Exchange
  • COUR Nasdaq
  • LQDA Nasdaq
  • Market Cap
  • COUR 1.5B
  • LQDA 1.2B
  • IPO Year
  • COUR 2021
  • LQDA 2018
  • Fundamental
  • Price
  • COUR $8.75
  • LQDA $13.05
  • Analyst Decision
  • COUR Hold
  • LQDA Strong Buy
  • Analyst Count
  • COUR 13
  • LQDA 9
  • Target Price
  • COUR $10.37
  • LQDA $27.67
  • AVG Volume (30 Days)
  • COUR 1.4M
  • LQDA 2.8M
  • Earning Date
  • COUR 07-24-2025
  • LQDA 08-06-2025
  • Dividend Yield
  • COUR N/A
  • LQDA N/A
  • EPS Growth
  • COUR N/A
  • LQDA N/A
  • EPS
  • COUR N/A
  • LQDA N/A
  • Revenue
  • COUR $704,874,000.00
  • LQDA $14,144,000.00
  • Revenue This Year
  • COUR $6.70
  • LQDA $185.38
  • Revenue Next Year
  • COUR $4.88
  • LQDA $350.95
  • P/E Ratio
  • COUR N/A
  • LQDA N/A
  • Revenue Growth
  • COUR 7.25
  • LQDA N/A
  • 52 Week Low
  • COUR $5.76
  • LQDA $8.26
  • 52 Week High
  • COUR $11.74
  • LQDA $19.41
  • Technical
  • Relative Strength Index (RSI)
  • COUR 55.50
  • LQDA 36.59
  • Support Level
  • COUR $8.34
  • LQDA $12.85
  • Resistance Level
  • COUR $8.58
  • LQDA $13.83
  • Average True Range (ATR)
  • COUR 0.25
  • LQDA 0.82
  • MACD
  • COUR -0.00
  • LQDA -0.25
  • Stochastic Oscillator
  • COUR 67.57
  • LQDA 5.41

About COUR Coursera Inc.

Coursera Inc is an online learning platform that connects learners, educators, and institutions with the goal of providing educational content that is affordable, accessible, and relevant. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The company operates through three reporting segments: Consumer, Enterprise, and Degrees. The majority of revenue is generated from the Consumer segment. The consumer segment targets individual learners seeking to obtain hands-on learning, gain valuable job skills, receive professional-level certifications, and otherwise increase their knowledge to start or advance their careers.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: